Skip to main content
Journal cover image

Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.

Publication ,  Journal Article
Bramlette, TB; Lawson, DH; Washington, CV; Veledar, E; Johns, BR; Brisman, SF; Abramova, L; Chen, SC
Published in: Dermatol Surg
January 2007

BACKGROUND: Patients with thick (Breslow>4 mm) primary melanoma and/or regional nodal metastasis have a high risk of tumor recurrence. High-dose adjuvant interferon (IFN) alfa-2b offers

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Dermatol Surg

DOI

ISSN

1076-0512

Publication Date

January 2007

Volume

33

Issue

1

Start / End Page

11 / 16

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Sentinel Lymph Node Biopsy
  • Recombinant Proteins
  • Patient Acceptance of Health Care
  • Middle Aged
  • Melanoma
  • Male
  • Interferon-alpha
  • Interferon alpha-2
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bramlette, T. B., Lawson, D. H., Washington, C. V., Veledar, E., Johns, B. R., Brisman, S. F., … Chen, S. C. (2007). Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Dermatol Surg, 33(1), 11–16. https://doi.org/10.1111/j.1524-4725.2007.33001.x
Bramlette, Tracy B., David H. Lawson, Carl V. Washington, Emir Veledar, Barry R. Johns, Stacey F. Brisman, Liana Abramova, and Suephy C. Chen. “Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.Dermatol Surg 33, no. 1 (January 2007): 11–16. https://doi.org/10.1111/j.1524-4725.2007.33001.x.
Bramlette, Tracy B., et al. “Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.Dermatol Surg, vol. 33, no. 1, Jan. 2007, pp. 11–16. Pubmed, doi:10.1111/j.1524-4725.2007.33001.x.
Bramlette TB, Lawson DH, Washington CV, Veledar E, Johns BR, Brisman SF, Abramova L, Chen SC. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Dermatol Surg. 2007 Jan;33(1):11–16.
Journal cover image

Published In

Dermatol Surg

DOI

ISSN

1076-0512

Publication Date

January 2007

Volume

33

Issue

1

Start / End Page

11 / 16

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Sentinel Lymph Node Biopsy
  • Recombinant Proteins
  • Patient Acceptance of Health Care
  • Middle Aged
  • Melanoma
  • Male
  • Interferon-alpha
  • Interferon alpha-2
  • Humans